

BIOTRANSFORMATION OF ANTITUMOR AGENTS BY A STRAIN OF *WHETZELINIA SCLEROTIORUM*

HENRY SCHMITZ and C. A. CLARIDGE

Research Division, Bristol Laboratories
Syracuse, New York 13201, U. S. A.

(Received for publication May 16, 1977)

Antitumor antibiotics of the olivomycin and chromomycin class were transformed when incubated with a culture of *Whetzelinia sclerotiorum*. The products, when purified by counter-current distribution and column chromatography, were shown, by their physical properties, to be the deacylated analogues.

In the course of screening microorganisms for the ability to modify known antitumor agents, we identified a strain of *Whetzelinia sclerotiorum* which transformed several compounds related to aureolic acid¹⁾. As substrates we used compounds isolated in our laboratories: NSC-A649²⁾, an antibiotic which was subsequently characterized and named olivomycin by Russian workers^{3,4)} and NSC-135052, (D. E. NETTLETON, unpublished results) which we identified as a mixture of chromomycins A₂ and A₃⁵⁾. The structures of these compounds had been elucidated by Russian^{3,4)} and Japanese⁵⁾ investigators.

The transformed substances were isolated from complex mixtures by methods similar to those employed for the starting materials. Their identities were established by comparison of TLC, IR, PMR and empirical formulas of the original and the transformed compounds and their acetates.

Experimental

Cultivation of the organism

Whetzelinia sclerotiorum ATCC-10939 was maintained on slants of BENNETT's medium⁶⁾ at 4°C. To prepare a seed culture, the growth of the slant was transferred aseptically to 25 ml of the following medium in a 125-ml Erlenmeyer flask and incubated for 48 hours at 27°C on a rotary shaker at 250 rpm: glucose 3%, lactose 1%, corn steep liquor 3% v/v, (NH₄)₂SO₄ 0.2%, KH₂PO₄ 0.05%, CaCO₃ 0.25%. This seed culture was transferred to 100 ml of the same medium contained in 500-ml Erlenmeyer flasks for an additional 48 hours incubation under the same conditions. The growth from these flasks was used to inoculate 500-ml Erlenmeyer flasks containing 100 ml of the following medium: lactose 3.75%, Pharmamedia 2%, CaCO₃ 0.5%, CaSO₄·2H₂O 0.25%, Na₂SO₄ 0.2%. After 48 hours of incubation at 27°C on a rotary shaker at 250 rpm, the compound to be transformed, dissolved in DMF, was added to give a final concentration of 1 mg/ml. The transformation was allowed to continue with further incubation on the shaker for 18~20 hours.

Preparation of substrates

Olivomycin A and chromomycin A₂ and A₃ were isolated and purified according to published procedures^{3,4,5)}. The major component from NSC-A649 gave IR and PMR spectra and elemental analysis, UV and visible spectra identical with those reported for olivomycin A. The optical rotation varied with the magnesium content of the samples and gave $[\alpha]_D^{25} +146^\circ$ for a magnesium complex and -26° for the free acid (*c* 0.5, ethanol) compared to reported values of -18° to -21° .

Culture NSC-135052 yielded mostly chromomycin A₂, a small amount of A₃ and traces of A₁ and A₄⁵⁾. The major components were identified by TLC, IR, UV, PMR spectra and elemental analysis. The optical rotation, as in the case of olivomycin, varied with the magnesium content. The free acid

chromomycin A₂ had $[\alpha]_D^{25} - 52.8^\circ$ (*c* 0.5, ethanol) (reported: -31° to -61°). A magnesium complex gave $[\alpha]_D^{25} - 52.8^\circ$ under the same conditions.

Isolation of transformed products

The broths from the *Whetzelinia sclerotiorum* cultures were filtered and extracted twice with one-third volumes of methylene chloride. The extracts were concentrated to an oil, the residue washed with petroleum ether, and dissolved in a minimum amount of ethyl acetate. The solution was diluted with an equal volume of ether, and the crude solids precipitated by the addition of petroleum ether.

The crude material was subjected to counter-current distribution in the solvent mixtures water-saturated *n*-butanol - 5% ethyl acetate in ether (1:1) or ethyl acetate - methanol - Skellysolve B - water (8:5:5:5:7). Purified compounds were chromatographed on silica gel (Grace-Davidson, Chemical Grade 62) activated at 110°C for 4 hours, using benzene-acetone gradient elution or a 1% solution of oxalic acid in ethyl acetate. No single method yielded pure compounds.

Fractions appearing homogeneous on TLC-bioautographs were crystallized from ethyl acetate-Skellysolve B. Thin-layer chromatograms were obtained on silica gel plates (EM Reagents, 60F 254 or Analtech Uniplates) with solvent mixtures methanol - chloroform - acetone - 17% ammonium hydroxide (3:8:8:1) or chloroform-methanol-formic acid (85:15:1). The zones were localized by bioautographs with *Bacillus subtilis* ATCC 6633.

PMR spectra were obtained with Varian HA 100 and XL instruments. Magnesium was determined by energy X-ray analysis by Dr. D. L. JOHNSON, College of Environmental Science and Forestry, Syracuse, New York. Antimicrobial activity was assayed by two-fold tube dilution in nutrient broth of overnight cultures as indicated in Table 1.

Results and Discussion

Olivomycin A

The transformed material, m. p. 140~142°C, had $[\alpha]_D^{25} - 34.4^\circ$ for the magnesium-free compound and $+40.5^\circ$ for a magnesium complex (*c* 0.5, ethanol). The λ_{max} (log E) in ethanol were: 406, 318, 273, 225 nm (4.11, 3.69, 4.63, 4.31). The carbonyl absorption in the IR spectrum was less intense than that of olivomycin A. The PMR spectra in the region 1.1~1.4 ppm of the parent and transformed compounds indicated the loss of the isobutyryl group of olivomycin A, the presence of one acetyl at 2.15 ppm, two methoxyls at 3.3 and 3.5 ppm, and three aromatic protons at 6.8, 7.1 and 7.3 ppm.

Table 1. The antibacterial spectrum of olivomycin A, chromomycin A₂ and their derivatives

Organism	Dilution	MIC (mcg/ml)			
		Olivomycin A	Deisobutyryl olivomycin A	Chromomycin A ₂	Deisobutyryl chromomycin A ₂
<i>Streptococcus pneumoniae</i> A9585	10 ⁻³	0.03	4	0.06	0.06
<i>Streptococcus pyogenes</i> A9604	10 ⁻³	0.06	4	0.06	0.06
<i>Staphylococcus aureus</i> Smith A9537	10 ⁻⁴	0.06	4	0.13	0.13
<i>Staphylococcus aureus</i> Smith + 50% Human Serum A9537	10 ⁻⁴	2	> 63	2	32
<i>Staphylococcus aureus</i> BX1633 A9606	10 ⁻³	0.06	32	0.13	0.13
<i>Staphylococcus aureus</i> BX1633 A9606	10 ⁻²	63	> 125	16	> 125
<i>Staphylococcus aureus</i> Methicillin resistant A15097	10 ⁻³	0.03	16	0.13	0.13

References

- 1) PHILIP, J. E. & J. R. SCHENCK: Aureolic acid, a new antibiotic. *Antibiot. & Chemoth.* 3: 1218~1220, 1953
- 2) SCHMITZ, H.; B. HEINEMANN, J. LEIN & I. R. HOOPER: NSC-A649, an antitumor antibiotic. *Antibiot. & Chemoth.* 10: 740~746, 1960
- 3) BRAZHNIKOVA, M. G.; E. G. KRUGLIAK, I. N. KOVSHAROVA, N. C. KONSTANTINOVA & V. V. PROSHLIAKOVA: The isolation, purification and study of certain physicochemical properties of the new antibiotic olivomycin. *Antibiotiki* 7: 39~44, 1962
- 4) BERLIN, YU. A.; S. E. ESPIOV, M. N. KOLOSOV & M. M. SHEMYAKIM: The structure of the olivomycin-chromomycin antibiotics. *Tetrahedron Letters* 1966: 1642~1647, 1966
- 5) MIYAMOTO, M.; Y. KAWAMATSU, M. SHINOHARA & K. NAKANISHI: The full structures of three chromomycins, A₂, A₃ and A₄. *Tetrahedron Letters* 1966: 545~552, 1966
- 6) JONES, K. L.: Fresh isolates of actinomycetes in which the presence of sporogenous aerial mycelia is a fluctuation characteristic. *J. Bact.* 57: 141~145, 1949